Study details
Enrolling now
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Franziska Wachter
NCT IDNCT05796570ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
37
Study length
about 6.4 years
Ages
1–39
Locations
2 sites in MA
About this study
This trial is testing whether it's possible to give decitabine and filgrastim after a stem cell transplant in children and young adults with certain blood cancers. The treatment aims to prevent the cancer from returning after the transplant.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Decitabine
- 2.Take Filgrastim
PhasePhase 2
DrugDecitabine
Routeinjection
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
decitabine, filgrastim
Drug routes
injection, intravenous, injection (Injection)
Endpoints
Secondary: 24-Month Probability Event-Free Survival (EFS), 24-Month Probability Overall Survival (OS), Treatment Tolerability Rate (TTR)
Body systems
Oncology, Musculoskeletal